Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer

This publication has 23 references indexed in Scilit:

• Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer after Complete Resection: An Updated Practice Guideline
  Clinical Oncology, 2011
• Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
  Annals of Oncology, 2010
• Reproducibility of the Rapid Bud Count Method for Assessment of Tumor Budding in Stage II Colorectal Cancer
  American Journal of Surgical Pathology, 2010
• CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer
  British Journal of Cancer, 2009
• Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups
  Cancer, 2009
• Local Recurrence in Mismatch Repair–Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
  Clinical Cancer Research, 2008
• Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy
  Diseases of the Colon & Rectum, 2008
• Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer?
  The Lancet Oncology, 2006
• Evolution of intratumoral genetic heterogeneity during colorectal cancer progression
  Carcinogenesis, 2005
• Histologic indices in biopsy specimens for estimating the probability of extended local spread in patients with rectal carcinoma
  Cancer, 2002